The licensing agreement grants AstraZeneca full control over the development and commercialization of Zegfrovy, a treatment currently approved in the United States and China for adults battling metastatic or locally advanced non-small cell lung cancer. Beyond the substantial upfront payment, Dizal stands to capture an additional $900 million tied to regulatory and commercial milestones, alongside tiered royalties from future global sales.

Investors reacted sharply to the news, pushing Dizal shares to 67.60 yuan, or roughly $9.98, marking the maximum allowable daily gain for the second consecutive session. This partnership highlights a broader industry shift as multinational pharmaceutical giants increasingly look toward China to replenish their portfolios with innovative, late-stage clinical assets.